Scholar Rock Holding (SRRK) Net Income towards Common Stockholders (2017 - 2026)

Scholar Rock Holding (SRRK) recorded quarterly Net Income towards Common Stockholders of -$101.4 million in Q1 2026, down 11.53% quarter-over-quarter from -$90.9 million in Q4 2025, and down 35.76% on a YoY basis from -$157.8 million in Q1 2025.

Scholar Rock Holding (SRRK) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$101.4 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 35.76% year-over-year to -$101.4 million; the TTM figure through Mar 2026 stood at -$404.3 million (down 53.13% YoY), while the FY2025 annual figure was -$205000.0, up 99.92% from the prior year.
  • Net Income towards Common Stockholders was -$101.4 million for Q1 2026 at Scholar Rock Holding, down from -$90.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$6.9 million in Q1 2022 to a low of -$109.9 million in Q2 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$60.6 million across 5 years, with a median of -$56.8 million in 2024.
  • The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders surged 74.52% in 2022, then sank 484.29% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$40.4 million in 2022, then fell by 18.81% to -$48.0 million in 2023, then plunged by 38.33% to -$66.4 million in 2024, then slumped by 36.82% to -$90.9 million in 2025, then fell by 11.53% to -$101.4 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$101.4 million (Q1 2026), -$90.9 million (Q4 2025), and -$102.2 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -13.56 Mn
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 2.50 Mn
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -14.46 Mn
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -3.63 Mn
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 1.03 Bn
9 Abivax 90.15 Bn 90.15 Bn - -56.48 Mn
10 Scholar Rock Holding 5.62 Bn 5.14 Bn - -101.38 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -101.38 Mn
Dec 31, 2025 -90.90 Mn
Sep 30, 2025 -102.15 Mn
Jun 30, 2025 -109.90 Mn
Mar 31, 2025 -74.68 Mn
Dec 31, 2024 -66.44 Mn
Sep 30, 2024 -64.44 Mn
Jun 30, 2024 -58.49 Mn
Mar 31, 2024 -56.83 Mn
Dec 31, 2023 -48.03 Mn
Sep 30, 2023 -43.67 Mn
Jun 30, 2023 -39.08 Mn
Mar 31, 2023 -40.51 Mn
Dec 31, 2022 -40.43 Mn
Sep 30, 2022 -43.86 Mn
Jun 30, 2022 -43.15 Mn
Mar 31, 2022 -6.93 Mn
Dec 31, 2021 -35.36 Mn
Sep 30, 2021 -37.08 Mn
Jun 30, 2021 -30.27 Mn